Skip to main content
Premium Trial:

Request an Annual Quote

Exact Sciences Nets $73.4M in Public Offering

NEW YORK (GenomeWeb News) – Exact Sciences today said that it raised $73.4 million in net proceeds from a previously announced public offering of its common stock.

The firm sold 6,325,000 shares at $12.35 per share, bringing in $78.1 million in gross proceeds.

Net proceeds will be used for general corporate and working capital purposes, including product development and efforts toward receiving US Food and Drug Administration approval for its Cologuard colorectal cancer screening test, as well as other product commercialization activities. The Madison, Wis.-based company filed the third and final premarket approval module to FDA for Cologuard earlier this month.

Jefferies and R.W. Baird acted as joint book-running managers on the offering. William Blair, Canaccord Genuity, and Mizuho Securities were co-managers.

The Scan

Rise of BA.5

The New York Times reports that the Omicron subvariant BA.5 has become the dominant version of SARS-CoV-2 in the US.

UK Health Secretary Resigns

Sajid Javid, the UK health secretary, resigned along with Chancellor Rishi Sunak, saying they cannot work with Prime Minister Boris Johnson's government, CNN reports.

Clones From Freeze-Dried Cells

A team in Japan has cloned mice from freeze-dried skin cells, according to the Guardian.

Genome Research Papers on Craniosynostosis, Macaque Retrotransposition, More

In Genome Research this week: structural variants in craniosynostosis, LINE-1 activity in rhesus macaque brain, and more.